Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).

In a multi-center randomized controlled trial conducted among Chinese patients with hypercholesterolemia, Ebronucimab, administered at 450 mg every 4 weeks or 150 mg every 2 weeks, significantly reduced serum LDL-C levels over 12 weeks (by approximately 59.13% and 60.43%, respectively), and showed high LDL-C goal achievement rates across different cardiovascular risk categories[1].